Amgen (AMGN) Equity Income (2020 - 2025)
Amgen (AMGN) recorded quarterly Equity Income of $10.0 million in Q3 2025, up 155.56% quarter-over-quarter from -$18.0 million in Q2 2025, and up 135.71% on a YoY basis from $4.2 million in Q3 2024.
Amgen (AMGN) Equity Income (2020 - 2025) Analysis & Trends
Amgen's Equity Income history runs 6 years deep, the most recent figure standing at $10.0 million for Q3 2025.
- In Q3 2025, Equity Income rose 135.71% year-over-year to $10.0 million; the TTM figure through Sep 2025 stood at -$20.0 million (down 17.65% YoY), while the FY2024 annual figure was $10.0 million, up 190.91% from the prior year.
- Equity Income was $10.0 million for Q3 2025 at Amgen, up from -$18.0 million in the prior quarter.
- In the past five years, Equity Income ranged from a high of $97.0 million in Q4 2021 to a low of -$305.0 million in Q1 2022.
- Historically, Equity Income has averaged -$31.0 million across 5 years, with a median of -$11.0 million in 2025.
- The sharpest annual moves came in 2022 and 2024: Equity Income sank 671.43% in 2022, then jumped 142.86% in 2024.
- A 5-year view of Equity Income shows it stood at $97.0 million in 2021, then tumbled by 283.51% to -$178.0 million in 2022, then surged by 84.27% to -$28.0 million in 2023, then soared by 96.43% to -$1.0 million in 2024, then jumped by 1100.0% to $10.0 million in 2025.
- The last three Equity Income figures came in at $10.0 million (Q3 2025), -$18.0 million (Q2 2025), and -$11.0 million (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | -5.39 Mn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | - |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | - |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | - |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | - |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | - |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | -3.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 10.00 Mn |
| Jun 30, 2025 | -18.00 Mn |
| Mar 31, 2025 | -11.00 Mn |
| Dec 31, 2024 | -1.00 Mn |
| Sep 30, 2024 | -28.00 Mn |
| Jun 30, 2024 | 12.00 Mn |
| Mar 31, 2024 | 27.00 Mn |
| Dec 31, 2023 | -28.00 Mn |
| Sep 30, 2023 | 14.00 Mn |
| Jun 30, 2023 | -28.00 Mn |
| Mar 31, 2023 | 31.00 Mn |
| Dec 31, 2022 | -178.00 Mn |
| Sep 30, 2022 | -104.00 Mn |
| Jun 30, 2022 | -80.00 Mn |
| Mar 31, 2022 | -305.00 Mn |
| Dec 31, 2021 | 97.00 Mn |
| Sep 30, 2021 | -98.00 Mn |
| Jun 30, 2021 | 14.00 Mn |
| Mar 31, 2021 | 85.00 Mn |
| Dec 31, 2020 | 78.00 Mn |